The NeurologyLive® dementia and Alzheimer disease clinical focus page provides information, podcasts, videos, and news about the latest FDA actions, clinical guideline updates, study and clinical trial findings, and interviews with physicians related to the care of patients with dementia and similar diseases, including Lewy body dementia, frontotemporal dementia, Alzheimer disease, and more.
September 1st 2025
Research reveals that increased sedentary time significantly impacts neurodegeneration and cognitive decline in older adults, especially those genetically at risk for Alzheimer’s.
Early-Onset Alzheimer Disease May Be Influenced by LDL-C Levels, APOB Gene
June 3rd 2019The findings from an analysis of more than 2000 plasma samples suggest that levels of low-density lipoprotein cholesterol, independent of APOE, are associated with early-onset Alzheimer disease—and that the APOB gene may play a role.
WHO Releases Guidelines for Reducing Risk for Dementia and Cognitive Decline
May 15th 2019The WHO guidelines specifically promote a healthy lifestyle, including regular exercise, not smoking, avoiding the harmful use of alcohol, maintaining a healthy weight and diet, and keeping healthy levels of blood pressure, cholesterol, and blood sugar.
Amit Rakhit, MD, MBA: Developing Therapies for Fragile X Syndrome
May 8th 2019The chief medical officer and head of Research & Development at Ovid Therapeutics spoke about the Visual Analog Scale that the company developed to help better understand the impact that potential treatments have on patients with Fragile X syndrome.
Diagnostic Guidelines Developed for LATE, New Alzheimer-Like Brain Disorder
May 2nd 2019The report includes consensus-based recommendations, which consist of guidelines for the diagnosis and staging of LATE-neuropathological change—defined by stereotypical TDP-43 proteinopathy both with or without simultaneous hippocampal sclerosis pathology, in older adults.
Sleep Apneas Show Association With Tau Accumulation in Cognitively Unimpaired
May 1st 2019Researchers found that cognitively unimpaired patients with apneas had an average of 4.5% higher levels of tau in the entorhinal cortex than those who did not have apneas, after controlling for several other factors.
PEGASUS Trial Investigators Bet on Combination Approach AMX0035 for Alzheimer Disease
April 11th 2019The PEGASUS principal investigator and Translational Neurology Head of the Interdisciplinary Brain Center at Massachusetts General Hospital and Harvard Medical School spoke about the Amylyx Pharmaceuticals product’s potential in Alzheimer.